Key result
Angiotensin-converting enzyme inhibitors can control interstitial inflammation and progression of chronic proteinuric nephropathies by strengthening the glomerular permeability barrier to proteins.
Why the study?
Do angiotensin-converting enzyme inhibitors and multimodal risk factor reduction improve remission rates in patients with chronic proteinuric nephropathies?
Do angiotensin-converting enzyme inhibitors and multimodal risk factor reduction improve remission rates in patients with chronic proteinuric nephropathies?
ACE inhibitors and multimodal risk factor reduction can limit proteinuria and potentially induce remission in patients with chronic proteinuric nephropathies.
No takes yet. Share an insight, caveat, or question.
May support ACE inhibitor use in proteinuric nephropathies; leaves open whether multimodal reduction improves remission rates.
Remuzzi et al. (2002) conducted a review in Chronic renal diseases, proteinuric nephropathies. Angiotensin-converting enzyme inhibitors was evaluated. Angiotensin-converting enzyme inhibitors can control interstitial inflammation and progression of chronic proteinuric nephropathies by strengthening the glomerular permeability barrier to proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: